Major advances have been made in recent years in the field of precision oncology. However, this therapeutic area still has significant challenges, such as determining those who are at an elevated cancer risk, developing techniques for earlier detection, predicting therapeutic response, gaining deeper insights into resistance mechanisms, and monitoring recurrence.
For these reasons, it is widely agreed that if it were possible to extend the scope of liquid biopsy techniques beyond nucleic acids to include proteins, it would allow researchers to retrieve the key functional biological signals that indicate both tumor biology and host response.
The eBook Protein biomarkers across the cancer continuum draws upon a series of influential, peer-reviewed studies to explore the possible applications of high-dimensional proteomics across the entire cancer continuum: from risk profiling and early detection to therapeutic assessment, response monitoring, toxicity analysis, and determining the chances of relapse.
Proteins measured in minimally invasive biofluids allow researchers the chance to address some of the most crucial questions in translational oncology, including:
- Which individuals are at increased risk of developing cancer?
- Can the disease be identified prior to clinical presentation?
- Which molecular features are associated with key responses to therapy?
- What is the relationship between biological mechanisms and treatment resistance?
- Is it possible to predict treatment-related toxicity and understand its fundamental mechanics?
- Which circulating biomarkers are related to disease recurrence?
© 2026 Olink Proteomics AB, part of Thermo Fisher Scientific. Olink products and services are For Research Use Only. Not for use in diagnostic procedures.
About Olink®- Part of Thermo Fisher Scientific
Olink’s mission is to accelerate proteomics together with the scientific community, to understand real-time biology and gain actionable insights into human health and disease. Our innovative solutions deliver highly sensitive and accurate protein quantification, giving scientists the power to investigate complex biological processes with precision.
One platform. Endless possibilities.
Explore up to 5,400 proteins with high specificity, transparent data, and the flexibility to answer any research question. Meet the next-generation proteomics platform trusted by the scientific community, from small academic research teams through to leading pharma companies.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.